The company chart indicates it’s highest volume day was est.2.2 million shares, which todays pace should eclipse before the open/
The company announced FDA fast track designation
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions
NEW YORK, May 25, 2022 /PRNewswire/ –Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab is currently being evaluated in the ongoing Phase 2 CRESTONE study, for which initial data will be presented in an oral presentation at the upcomingAmerican Society of Clinical Oncology (ASCO) 2022 Annual Meeting on Tuesday, June 7, 2022.
